EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Precipio's enterprise value is $7.91 Mil.
Precipio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $15.20 Mil. Therefore, Precipio's EV-to-Revenue for today is 0.52.
The historical rank and industry rank for Precipio's EV-to-Revenue or its related term are showing as below:
PRPO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -4.04 Med: 3.42 Max: 21.9
Current: 0.52
During the past 13 years, the highest EV-to-Revenue of Precipio was 21.90. The lowest was -4.04. And the median was 3.42.
PRPO's EV-to-Revenue is ranked better than 88.89% of 225
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.04
vs PRPO: 0.52
As of today (2024-05-05), Precipio's stock price is $5.80.
Precipio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $11.62. Therefore, Precipio's PS Ratio for today is 0.50.
Precipio EV-to-Revenue Historical Data
The historical data trend for Precipio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Precipio's EV-to-Revenue
For the Diagnostics & Research subindustry, Precipio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Precipio's EV-to-Revenue falls into.
Precipio's current Enterprise Value is $7.91 Mil.
Precipio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio's share price for today is $5.80.
Precipio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.62.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Precipio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRPO has been successfully added to your 